Nucleus RadioPharma to manufacture the cancer drug 67Cu-SAR-bisPSMA for Clarity Pharmaceuticals, a clinical-stage company focusing on radiopharmaceuticals. Under the agreement, Nucleus RadioPharma, a contract development and manufacturing organisation (CDMO), will produce the drug at its state-of-the-art facility in Rochester, Minnesota,
BrainStorm Cell Therapeutics Inc. announced a partnership with Pluri Inc. to support the manufacturing of its NurOwn cellular therapy for an upcoming Phase 3b trial targeting amyotrophic lateral sclerosis (ALS). The agreement, established through a Memorandum of Understanding (MOU), allows
GenScript Biotech Corporation has announced the opening of a new operations site and logistics center in Sydney, Australia. This expansion aims to streamline the delivery of biotechnology research materials across the region, marking GenScript’s increased commitment to the Asia-Pacific market.
Samsung Biologics has been awarded the ISO 37301:2021 certification for Compliance Management Systems, recognising the company’s commitment to organisational governance and adherence to global regulatory standards. This new certification, presented by the British Standards Institution (BSI), underlines Samsung Biologics’ ongoing
Maravai LifeSciences, announced it will acquire the DNA and RNA business of Officinae Bio, an Italy-based biotechnology company. This move aims to strengthen Maravai and its subsidiary, Trilink BioTechnologies, in advancing nucleic acid-based therapeutic development. Officinae Bio, headquartered in Venice,
Aptar Pharma has announced an exclusive collaboration with Cambridge Healthcare Innovations (CHI) to lead the commercialisation of the Quattrii Dry Powder Inhaler (DPI) platform. Through this agreement, Aptar Pharma will serve as the primary contact for customers and prepare the
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030. However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well
Transgene a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a CDMO in biologics, vaccines and viral vectors have entered a licensing agreement to advance manufacturing capabilities for personalised cancer vaccines using ProBioGen’s
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on central nervous system (CNS) cancers, has entered a Manufacturing Services Agreement (MSA) with SpectronRx, a radiopharmaceutical contract development and manufacturing organisation (CDMO). The partnership will enable the production of
Matica Biotechnology, a contract development and manufacturing organization (CDMO) specialising in viral vectors, has unveiled a new high-resolution ion-exchange chromatography (IEX) method designed to improve the analysis of AAV8 (Adeno-Associated Virus 8) viral vector capsids. This advancement addresses a key
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
